Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
暂无分享,去创建一个
[1] A. Gemma,et al. F1000 highlights , 2010 .
[2] David N Louis,et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.
[3] Michelle S. Ginsberg,et al. Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] J. Shih,et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma , 2010, Medical oncology.
[5] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[6] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[7] R. Wahl,et al. Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy , 2009 .
[8] L. Sequist,et al. Toward noninvasive genomic screening of lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Wood,et al. Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] M. Meyerson,et al. Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients , 2006, Clinical Cancer Research.
[11] H. Sasaki,et al. Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] A. Fischman,et al. Lipomatous hypertrophy of the interatrial septum: prevalence and features on fusion 18F fluorodeoxyglucose positron emission tomography/CT. , 2005, Chest.
[13] R. Deberardinis,et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.
[14] S. Digumarthy,et al. Fluorodeoxyglucose Positron Emission Tomography Pattern of Pulmonary Lymphangitic Carcinomatosis , 2005, Journal of computer assisted tomography.
[15] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[16] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[17] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[18] A. Alavi,et al. Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.
[19] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[20] R. Hustinx,et al. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] A. Fischman,et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. , 2002, Lung cancer.
[22] D. Wood,et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] Sung-Cheng Huang,et al. Anatomy of SUV , 2000 .
[24] Gerald J. Kutcher,et al. The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer , 2000 .
[25] R L Wahl,et al. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.
[26] M. Kalra,et al. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis. , 2010, AJR. American journal of roentgenology.
[27] Jae Cheol Lee,et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. , 2010, Lung cancer.
[28] V Kalff,et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.